



## The Future Direction of Radiopharmaceutical Development for Cancer Theranostics

Guest Editor:

**Dr. Martina Benešová-Schäfer**

Research Group Molecular  
Biology of Systemic  
Radiotherapy, Research Program  
Imaging and Radiooncology,  
German Cancer Research Center  
(DKFZ), Im Neuenheimer Feld  
223, 69120 Heidelberg, Germany

Deadline for manuscript  
submissions:  
**closed (31 January 2020)**

### Message from the Guest Editor

Dear Colleagues

The journal *Pharmaceuticals* is planning to publish a Special Issue covering the topic “The Future Direction of Radiopharmaceutical Development for Cancer Theranostics”, and I am cordially inviting you to contribute an article to this volume.

The purpose of this Special Issue is to host research and review papers on the development of novel radiopharmaceuticals and therapy strategies for cancer theranostics, which hold a great promise for improved patients' outcomes in the future. Areas of interest include, but are not limited to:

- Identification of new targets for cancer theranostics;
- Design of novel radiopharmaceuticals for cancer theranostics;
- Evaluation of non-standard radionuclides potentially suitable for cancer theranostics;
- Experimental targeted radionuclide therapy strategies;
- Prospective combination therapy with targeted radionuclide therapy involved.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)